HomeCompareATRI vs PFE

ATRI vs PFE: Dividend Comparison 2026

ATRI yields 1.91% · PFE yields 6.20%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ATRI wins by $693.7K in total portfolio value
10 years
ATRI
ATRI
● Live price
1.91%
Share price
$459.92
Annual div
$8.80
5Y div CAGR
70.5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$744.8K
Annual income
$498,113.36
Full ATRI calculator →
PFE
Pfizer Inc.
● Live price
6.20%
Share price
$27.76
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$51.1K
Annual income
$27,210.54
Full PFE calculator →

Portfolio growth — ATRI vs PFE

📍 ATRI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodATRIPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ATRI + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ATRI pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATRI
Annual income on $10K today (after 15% tax)
$162.64/yr
After 10yr DRIP, annual income (after tax)
$423,396.36/yr
PFE
Annual income on $10K today (after 15% tax)
$526.66/yr
After 10yr DRIP, annual income (after tax)
$23,128.96/yr
At 15% tax rate, ATRI beats the other by $400,267.40/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATRI + PFE for your $10,000?

ATRI: 50%PFE: 50%
100% PFE50/50100% ATRI
Portfolio after 10yr
$397.9K
Annual income
$262,661.95/yr
Blended yield
66.01%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

ATRI
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
26.0
Piotroski
6/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-0.9% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATRI buys
0
PFE buys
0
No recent congressional trades found for ATRI or PFE in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricATRIPFE
Forward yield1.91%6.20%
Annual dividend / share$8.80$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR70.5%13.2%
Portfolio after 10y$744.8K$51.1K
Annual income after 10y$498,113.36$27,210.54
Total dividends collected$700.3K$60.1K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusSellHold

Year-by-year: ATRI vs PFE ($10,000, DRIP)

YearATRI PortfolioATRI Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$11,026$326.23$9,161$701.38+$1.9KATRI
2$12,371$573.18$8,610$859.79+$3.8KATRI
3$14,262$1,024.75$8,366$1,081.25+$5.9KATRI
4$17,143$1,882.46$8,483$1,405.66+$8.7KATRI
5$21,948$3,605.53$9,084$1,907.24+$12.9KATRI
6$30,840$7,355.78$10,418$2,732.78+$20.4KATRI
7$49,469$16,469.85$13,007$4,193.56+$36.5KATRI
8$95,028$42,096.26$18,010$7,005.87+$77.0KATRI
9$230,536$128,855.34$28,216$12,979.89+$202.3KATRI
10$744,786$498,113.36$51,081$27,210.54+$693.7KATRI

ATRI vs PFE: Complete Analysis 2026

ATRIStock

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmology applications in the United States, Canada, Europe, and internationally. Its fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. The company's cardiovascular products comprise Myocardial Protection System that delivers fluids and medications and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. Its ophthalmic products include specialized medical devices that disinfect contact lenses; and a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. The company also manufactures instrumentation and associated disposables that measure the activated clotting time of blood; and products for safe needle and scalpel blade containment. In addition, it manufactures inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.

Full ATRI Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this ATRI vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATRI vs SCHDATRI vs JEPIATRI vs OATRI vs KOATRI vs MAINATRI vs JNJATRI vs MRKATRI vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.